Landmark Wealth Management LLC Makes New $86,000 Investment in Johnson & Johnson (NYSE:JNJ)

view original post

Landmark Wealth Management LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 862 shares of the company’s stock, valued at approximately $86,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Magnolia Capital Management Ltd. boosted its holdings in shares of Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after buying an additional 55 shares in the last quarter. Howard Financial Services LTD. boosted its holdings in shares of Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares in the last quarter. American Financial Advisors LLC boosted its holdings in shares of Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after buying an additional 57 shares in the last quarter. Capital Investment Counsel Inc boosted its stake in Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after purchasing an additional 59 shares during the period. Finally, Kwmg LLC boosted its stake in Johnson & Johnson by 2.6% during the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after purchasing an additional 59 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JNJ. Morgan Stanley increased their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Citigroup decreased their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. UBS Group cut their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday. Finally, Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $171.31 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock has a market cap of $450.79 billion, a P/E ratio of 24.94, a PEG ratio of 3.42 and a beta of 0.63. The company has a 50-day moving average of $176.35 and a two-hundred day moving average of $174.34. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.48 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.01 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.